Global Postmarket Pharmacovigilance: A Generic Drug Perspective

Area of Science:

• Pharmacovigilance
• Drug Safety
• Regulatory Science

Background:

• Harmonizing generic drug pharmacovigilance is crucial but understudied.
• International comparisons of postmarket safety surveillance for generics are limited.

Purpose of the Study:

• To overview decision-making processes for postmarket generic drug safety and surveillance.
• To compare pharmacovigilance approaches of international regulatory agencies.
• To identify common barriers in generic drug safety surveillance.

Main Methods:

• Utilized a structured questionnaire and semi-structured interviews.
• Collected data from Swissmedic, MHRA, Health Canada, and FDA.
• Analyzed similarities and differences in regulatory approaches.

Main Results:

• Participating agencies exhibit both similarities and differences in generic drug pharmacovigilance.
• Most agencies do not have distinct processes specifically for generic drugs.
• Identified legislative restrictions and resource limitations as common barriers.

Conclusions:

• Regulatory agencies generally lack unique postmarket surveillance processes for generic drugs.
• Findings underscore the need for increased global regulatory awareness and collaboration.
• Promoting cross-collaboration can enhance international generic drug safety efforts.